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Introduction
Infliximab (IFX) is a chimeric (human–murine) 
monoclonal IgG1 anti-tumor necrosis factor alpha 
(TNF-α) antibody used in the treatment of inflam-
matory bowel disease (IBD) [Bendtzen, 2013]. 
Although IFX has profoundly improved the treat-
ment of inflammatory diseases, not all patients 
respond to induction therapy, and up to 50% of 
patients experience the loss of clinical response 
over time (secondary loss of response) [Yanai and 
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Abstract: 
Background: There is scant information on the accuracy of different assays used to measure 
anti-infliximab antibodies (ADAs), especially in the presence of detectable infliximab (IFX). We 
thus aimed to evaluate and compare three different assays for the detection of IFX and ADAs 
and to clarify the impact of the presence of circulating IFX on the accuracy of the ADA assays.
Methods: Blood samples from 79 ulcerative colitis (UC) patients treated with infliximab were 
assessed for IFX levels and ADAs using three different assays: an in-house assay and two 
commercial kits, Immundiagnostik and Theradiag. Sera samples with ADAs and undetectable 
levels of IFX were spiked with exogenous IFX and analyzed for ADAs.
Results: The three assays showed 81–96% agreement for the measured IFX level. However, 
the in-house assay and Immundiagnostik assays detected ADAs in 34 out of 79 samples, 
whereas Theradiag only detected ADAs in 24 samples. Samples negative for ADAs with 
Theradiag, but ADA-positive in both the in-house and Immundiagnostik assays, were positive 
for IFX or IgG4 ADAs. In spiking experiments, a low concentration of exogenous IFX (5 µg/
ml) hampered ADA detection with Theradiag in sera samples with ADA levels of between 3 
and 10 µg/ml. In the Immundiagnostik assay detection interference was only observed at 
concentrations of exogenous IFX higher than 30 µg/ml. However, in samples with high levels 
of ADAs (>25 µg/ml) interference was only observed at IFX concentrations higher than 100 µg/
ml in all three assays. Binary (IFX/ADA) stratification of the results showed that IFX+/ADA- 
and IFX-/ADAs+ were less influenced by the assay results than the double-positive (IFX+/
ADAs+) and double-negative (IFX-/ADAs-) combination.
Conclusions: All three methodologies are equally suitable for measuring IFX levels. However, 
erroneous therapeutic decisions may occur when patients show double-negative (IFX-/ADAs-
) or double-positive (IFX+/ADAs+) status, since agreement between assays is significantly 
lower in these circumstances.
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Hanauer, 2011; Steenholdt et  al. 2013]. When 
managing loss of response, clinicians may empiri-
cally intensify treatment with the existing drug 
(increase dosage and/or increase frequency), 
switch to another TNF-α antagonist or switch to a 
totally different class of drug. This empirical 
approach has disadvantages: risk of irreversible tis-
sue damage while the physician searches for an 
effective new drug, and significant economic con-
sequences of unsuccessful trial and errors 
[Bendtzen and Svenson, 2011; Steenholdt et  al. 
2014a]. A more astute strategy is probably to use 
therapeutic drug monitoring (TDM), which ena-
bles clinicians to identify patients in whom a medi-
cation or change in medication is likely to be 
effective [Roblin et al. 2014; Steenholdt et al. 2014b; 
Yanai et  al. 2015]. Indeed, a rational evidence-
based and tailored therapy according to individual 
needs may reduce delays in effective treatment 
[Bendtzen, 2013; Steenholdt et al. 2014b].
Awareness of the value of TDM has led to the 
development of different techniques for assessing 
levels of infliximab and anti-infliximab antibodies 
(ADA) in patients, but these different methodol-
ogies have distinctive limitations and may yield 
different results. This potential bias may have a 
significant impact on TDM results and interpre-
tation. There is still little information allowing us 
to compare different assays, in particular in rela-
tion to ADAs detection, which is likely to be sub-
ject to interference by detectable levels of IFX 
[Casteele et  al. 2012; Kopylov et  al. 2012; 
Steenholdt et al. 2013].
In order to incorporate therapeutic drug moni-
toring into clinical practice it is pertinent to 
recognize the potential for assay heterogeneity 
and accuracy. Therefore, the objective of this 
study was to evaluate and compare three different 
methodologies used to detect IFX and ADA and 
to clarify the importance of detectable IFX levels 
when measuring ADA levels namely on the accu-
racy of ADA assays.
Methods
Patients and sera
Trough blood samples were collected from 79 
IFX treated ulcerative colitis (UC) patients. 
Blood samples were centrifuged, and the serum 
collected and stored at –80°C. This was a multi-
center, open-label, single-arm trial. Study partici-
pants were recruited from ten IBD centers in 
Portugal. The trial was conducted in accordance 
with the Declaration of Helsinki and Ethical 
Principles of Good Clinical Practice and was 
approved by the local Ethics Committees. All 
participants gave their written informed consent.
Evaluation of IFX levels
IFX levels were evaluated using a sandwich 
enzyme-linked immunosorbent assay (ELISA) 
from three different sources (Figure 1A): one in-
house ELISA and two commercial ELISA kits. 
The upper limit of the measurement for the three 
assays was calculated as the highest concentra-
tion of the standard curve × sample dilution fac-
tor used.
IFX levels were evaluated using the in-house 
ELISA as previously described by Baert and 
Figure 1. (A) Infliximab assays. (B) Anti-infliximab antibodies assays.
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colleagues with some modifications [Baert et al. 
2003; Ben-Horin et al. 2011]. Briefly, 100 ml of 
1:100 diluted serum was added to a plate pre-
coated with 750 ng/ml TNFα (Peprotech, Rocky 
Hill, NJ, USA) and incubated for 60 min. 
Following washing, horseradish peroxidase 
(HRP) labelled goat anti-human Fc fragment 
antibody (MP Biomedicals, Solon, OH, USA) at 
a concentration of 0.62 µg/ml was added for 60 
min. After washing, a 3-min reaction was per-
formed with tetramethylbenzidine (TMB) sub-
strate and stopped with H2SO4, 2 M. The results 
were read at 450/540 nm using a Power Wave 
340 (Biotec Instruments). The infliximab con-
centration was quantified using a standard curve 
constructed using exogenous infliximab (Schering 
Plough, NJ, USA). The lower limit of quantifica-
tion was 0.1 µg/ml.
IFX levels were also evaluated in parallel using 
the commercial TNFα-Blocker ELISA 
(Immundiagnostik AG, Germany) and Lisa-
Tracker Premium Infliximab ELISA (Theradiag, 
France) kits according to the instructions pro-
vided by the manufacturer. The lower limit of 
quantification was 0.5 and 0.1 µg/ml, for 
Immundiagnostik and Theradiag, respectively.
Evaluation of ADA levels
Antibodies to infliximab were evaluated using 
three distinct methodologies (Figure 1B), one in-
house assay [anti-human lambda chain assay 
(AHLC)], and two commercially available kits [a 
semi-quantitative assay, TNFα- Blocker ADA 
(Immundiagnostik AG, Germany); and a quanti-
tative assay, Lisa-Tracker Premium Infliximab 
ELISA (Theradiag, France)]. The upper limit of 
the measurement for the three assays was calcu-
lated as the highest concentration of the standard 
curve × sample dilution factor used.
In-house AHLC. ADA levels were determined in 
all samples using an in-house ELISA as previ-
ously described by Ben-Horin and colleagues 
[Ben-Horin et al. 2011]. The AHLC is a sandwich 
ELISA that uses anti-human lambda chain conju-
gate antibody in the detection step, taking advan-
tage of the exclusively kappa chain composition 
of IFX [Kopylov et al. 2012]. Briefly, IFX was 
added to a plate precoated with TNFα (Peprot-
ech, Rocky Hill, NJ, USA). After Diluted serum 
was added and incubated for 60 min at room 
temperature. Goat anti-human lambda chain 
HRP-labeled antibody (Serotec, Oxford, UK) 
was added and incubated for 60 min, at room 
temperature. After a 6-min reaction with TMB 
the reaction was stopped with H2SO4. Absor-
bances were read at 450/540 nm and the results 
are expressed as µg/ml-equivalent (µg/ml-e) after 
normalization against results obtained using a 
standard curve of goat anti-human F(ab’)2 frag-
ment antibody (MP Biomedicals). For the pur-
pose of brevity, the results are thereafter expressed 
as µg/ml, rather than µg/ml-e. The lower limit of 
quantification was 1.2 µg/ml.
Immundiagnostik semi-fluid phase enzyme immu-
noassay. ADA levels were determined in a semi-
fluid phase enzyme immunoassay (SFPE) using a 
commercial kit (TNFα-Blocker ADA) purchased 
from Immundiagnostik (Germany) according to 
the instructions provided by the manufacturer. 
The SFPE uses an initial acid buffer treatment to 
dissociate the IFX–ADA immune complexes and 
two IFX conjugates with different conjugates. 
Acidified samples are incubated with IFX–biotin 
conjugate which immobilizes ADAs on the plate, 
and IFX–peroxidase conjugate is used for detec-
tion [Imaeda et al. 2012].
Theradiag bridging ELISA. ADA levels were deter-
mined in a bridging ELISA (BE) performed using 
a commercial kit (Lisa-Tracker Premium Inflix-
imab ELISA) purchased from Theradiag (France) 
according to the instructions provided by the 
manufacturer. The BE uses a double-antigen 
bridge: ADAs create a bridge between IFX immo-
bilized on the plate and IFX enzyme-linked con-
jugate. A total of 4 out of 79 samples determined 
with Theradiag were higher than the upper limit 
of the kit: in these cases the upper limit was con-
sidered as the result. The lower limit of quantifi-
cation was 10 ng/ml.
Exogenous IFX in ADA-positive sera samples
Exogenous IFX (Schering Plough, NJ, USA) was 
used to spike ADA-positive sera samples that 
contained undetectable levels of IFX.
Evaluation of exogenous IFX incubation time. The 
incubation time of exogenous IFX in sera was 
evaluated. Sera samples with ADAs and unde-
tectable levels of IFX were incubated with sev-
eral concentrations of IFX (5, 10, 15, 30, 100 
and 300 µg/ml) for different lengths of time (0, 
0.5, 3, 6, 12 and 24 h). Levels of ADAs were then 
determined using the AHLC assay as described 
above.
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Evaluation of stratified ADA levels (four groups) 
with exogenous IFX spiking using AHLC methodol-
ogy. Four groups with undetectable IFX (<0.1 
µg/ml) were stratified according to ADA-positive 
concentration as previously measured by AHLC 
assay: group A (ADAs within 1.7–3 µg/ml); group 
B (ADAs within 3–10 µg/ml); group C (ADAs 
within 10–25 µg/ml); group D (ADAs >25 µg/
ml). Sera were preincubated with several concen-
trations of exogenous IFX (5, 10, 30, 100 and 300 
µg/ml) for 30 min, at room temperature. Levels of 
ADAs were then determined using the in-house 
AHLC ELISA as described above.
Evaluation of ADA levels with exogenous IFX 
spiking in two groups of sera samples using three 
different methodologies. Two groups of ADA-
positive sera with undetectable IFX (<0.1 µg/ml) 
were selected from sera previously measured by 
AHLC assay: high levels of ADAs (>25 µg/ml) 
and intermediate levels of ADAs (>3 µg/ml and 
<10 µg/ml). Sera were preincubated with several 
concentrations of exogenous IFX (5, 10, 15, 30, 
100 and 300 µg/ml) for 30 min, at room tempera-
ture. Levels of ADAs were then determined using 
the three different methodologies: in-house 
AHLC, Immundiagnostik SFPE and Theradiag 
BE as described above.
Measurement of ADA IgG4 in the sera
Sera samples containing ADAs were evaluated for 
ADA IgG4. ADA IgG4 levels were determined 
using an ELISA developed and described by 
Bendtzen and colleagues and adapted for IgG4 
detection [Bendtzen and Svenson, 2011; 
Steenholdt, 2013]. Briefly, diluted serum was 
added and incubated for 60 min at room tempera-
ture to a plate precoated with anti-IgG4 antibody 
(Serotec, Oxford, UK). Plates were then washed 
and HRP-labeled infliximab was added for 60 
min, at room temperature. A 5-min reaction with 
TMB substrate was performed and stopped with 2 
M H2SO4. Absorbances were read at 450/540 nm 
and the results were expressed as µg/ml-e after 
normalization against results obtained using a 
standard curve of goat anti-human F(ab’)2 frag-
ment antibody (MP Biomedicals).
Statistical analysis
The intraclass correlation coefficient (ICC) was 
used to determine the quantitative agreement 
between IFX levels evaluated by the three assays. 
ICC within 0.4 and 0.75 was considered 
moderate, lower than 0.4 poor and higher than 
0.75 excellent. Agreement between assays was 
also assessed using Bland–Altman analysis, in 
which the mean differences and limits of agree-
ment are descriptive. The KAPPA coefficients 
of 0–0.20 were considered to indicate slight, 
0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 
substantial and 0.81–1 almost perfect agreement 
[Landis and Koch, 1977]. The mean difference 
(bias) and its 95% confidence interval (CI) were 
computed. Limits of agreement (LOAs) were 
defined as mean difference ± 2 standard devia-
tions of difference (LOA = bias ± SDD). Ninety-
five per cent of differences are expected to lie 
between LOAs.
The quantitative agreement between assays for 
ADA could not be assessed because data were 
reported using different and arbitrary units 
(AU/ml).
Kappa coefficient and percentage agreement were 
therefore used to determine the qualitative agree-
ment between IFX levels, ADAs and status 
(IFX+/ADAs-; IFX+/ADAs+; IFX-/ADAs-; 
IFX-/ADAs-). Correlations between assays were 
determined only for IFX levels using linear cor-
relation analysis expressed as Pearson’s correla-
tion coefficient (Pearson’s r).
Results
IFX levels
A total of 79 sera samples were evaluated for IFX 
levels using three types of ELISA. Samples were 
collected from multicentric cohort of UC patients, 
composed of 44% men and with a median [inter-
quartile range (IQR)] age of 35 (23–48) years. All 
patients were in the maintenance phase (after 14 
weeks). A total of 35% of the patients were in IFX 
monotherapy and the remain cohort in concomi-
tant therapy [38% azathioprine (AZA); 12% 
5-aminosalicylic acid (5-ASA); 7% AZA + 5ASA; 
1% methotrexate; 1% corticosteroids; 2% AZA + 
5-ASA + corticosteroids; 1% AZA + corticoster-
oids + antibiotics].
Quantitative agreement was calculated using the 
ICC and mean differences (Table 1). Compari-
sons showed that ICC varied from a moderate 
agreement of 0.694 (0.618–0.805) between 
Immundiagnostik and Theradiag up to an excel-
lent agreement of 0.957 (0.933–0.972) between 
the in-house ELISA and Immundiagnostik kit. 
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Mean differences (bias) confirmed the ICC evalu-
ation. Moreover, a Bland and Altman plot analysis 
(graphics not shown) indicate that the significant 
bias between in-house and Theradiag is a result of 
dispersion of values along all of infliximab concen-
tration, even for minor concentrations. Regarding 
in-house and Immundiagnostik, bias is more sig-
nificant for concentrations higher than 15 µg/ml.
The Pearson correlation between different assays 
was also calculated: 0.84 (p<0.001) for in-house 
versus Theradiag; 0.79 (p < 0.001) for Theradiag 
versus Immundiagnostik and 0.92 (p<0.001) for 
in-house versus Immundiagnostik.
In order to quantify the qualitative agreement of 
the different methods, two different cutoffs were 
applied to the measured concentrations: one used 
the limit of detection determined by the manufac-
turers for each assay as the cutoff, conveying an 
analytical perspective; and the other used clini-
cally relevant cutoffs, as defined in the literature 
[Kopylov et al. 2012; Ungar et al. 2015].
Regarding the analytical approach, IFX was con-
sidered positive when above 0.1 µg/ml using the 
in-house and Theradiag methods. For the 
Immundiagnostik kit, positivity was considered for 
IFX concentrations above 0.5 µg/ml. The in-house 
ELISA technique detected trough levels in 61 of 
79 samples, a detection rate similar to that verified 
using the Immundiagnostik method (78%). Using 
Theradiag the IFX trough levels were detected in 
fewer sera (71%). The accuracy and KAPPA coef-
ficients for these methods using the analytical cut-
off are depicted in Table 2(A). In-house and 
Theradiag ELISA showed a moderate agreement 
(0.509), whereas the in-house/Immundiagnostik 
and Immundiagnostik/Theradiag had a substan-
tial agreement (0.69 and 0.726, respectively). 
Moreover, a good accuracy was found among the 
three assays (81–88%).
Considering the clinical approach, IFX was 
defined as positive for concentrations above 
1 µg/ml. The cutoff was settled taking in consid-
eration cutoffs reported previously in the litera-
ture [Kopylov et al. 2012; Ungar et al. 2015].
The in-house ELISA detected positive IFX 
trough levels in 48 of the 79 samples (61%), while 
the Immundiagnostik kit did so in 45 of the 79 
samples (57%) and the Theradiag kit did so in 49 
of the 79 samples (62%). The data regarding IFX 
trough levels obtained using the different assays is 
shown in Table 2(B).
The accuracy and KAPPA coefficient between 
the three different assays were calculated (Table 
2B). All assays showed excellent agreement 
regarding IFX levels, with the KAPPA coefficient 
ranging from 0.835 (0.709–0.960) between 
Immundiagnostik and Theradiag results, to 0.922 
(0.836–1.000) between the in-house assay and 
Immundiagnostik results. A high level of accuracy 
was found between the three assays, with the in-
house and Immundiagnostik assays showing the 
highest accuracy (96%).
ADA levels
The ICC and mean difference for ADAs could 
not be evaluated because the different assays 
used different units of measurement (µg/ml for 
in-house assay and Theradiag and AU/ml for 
Immundiagnostik).
From an analytical point of view, ADAs positivity 
was defined as levels above 1.2 µg/ml for in-house 
method, 0.01 µg/ml for the Theradiag kit and 10 
AU/ml for Immundiagnostik kit. All techniques 
have identified the same number of ADAs-
positive samples (46%). Accuracy and KAPPA 
coefficient were calculated and are depicted in 
Table 3(A): a good accuracy was found for the 
Table 1. Intraclass correlation (ICC) and mean differences between different assays.
ICC 95% CI Differences
 Mean 95% CI
IFX  
In-house ELISA/ Theradiag ELISA 0.762 0.627–0.848 3.99 2.63–5.36
In-house ELISA/ Immundiagnostik ELISA 0.957 0.933–0.972 –0.43 –1.31 to 0.44
Immundiagnostik ELISA / Theradiag ELISA 0.694 0.618–0.805 4.43 2.76–6.10
CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; IFX, infliximab.
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three assays (82–85%), whereas KAPPA coeffi-
cient shown a moderate agreement.
A clinical approach to the ADAs positivity is 
shown in Table 3(B). Samples were considered 
ADA-positive when levels exceeded 1.7 µg/ml for 
the in-house (AHLC) as applied by Kopylov and 
colleagues [Kopylov et al. 2012]. For Theradiag 
the same cutoff was applied. For the 
Immundiagnostik (SFPE) assay ADA-positive 
were considered when >10 AU (cutoff defined by 
the manufacturer for positivity). The in-house and 
Immundiagnostik assays detected ADAs in 34 out 
of 79 samples (43%), while Theradiag detected 
ADAs in 24 out of 79 samples (30%). Although 
the in-house and Immundiagnostik assays 
detected the same number of samples with ADAs 
not all samples matched. In fact, ADAs were con-
firmed by both the in-house and Immundiagnostik 
assay in 28 out of the 34 samples (82%). Regarding 
the comparative performance of Theradiag with 
the in-house and Immundiagnostik assays, of the 
24 samples with ADAs identified by Theradiag, 
21 (87.5%) were also positive in both the in-house 
and Immundiagnostik assays. Nevertheless, the 
in-house and Immundiagnostik assays considered 
positive 13 and 12 samples, respectively, that were 
negative with Theradiag.
Moderate agreement was found between the in-
house and Theradiag assays, with a KAPPA coef-
ficient of 0.602 (0.435–0.769) while the in-house 
and Immundiagnostik assays showed good agree-
ment with a KAPPA coefficient of 0.692 (0.531–
0.852). Accuracy ranged from 81% to 85% 
among the different pairs of assays (Table 3B).
IFX and ADA status
Figure 2 depicts the levels of IFX and ADAs eval-
uated by all assays. The vertical dotted line sepa-
rates samples positive for IFX from samples 
negative for IFX. The horizontal dotted line sepa-
rates samples positive for ADAs from samples 
negative for ADAs. Both analytical and clinical 
perspectives are represented in Figure 2. From 
the analytical point of view, 71–77% of total sam-
ples are included in IFX+ group, and 45% in 
anti-IFX+. On the other hand, from a clinical 
perspective all the three assays identified 25% of 
samples positive for ADAs and IFX-negative. 
Table 2. Agreement between different assays 
regarding levels of IFX: (A) analytical approach and 
(B) clinical approach.
Agreement
 Accuracy KAPPA
[95% CI]
(A) IFX
(>0.1 µg/ml in-house and Theradiag; 0.5 µg/ml 
Immundiagnostik)
In-house ELISA/ 
Theradiag ELISA
81% 0.509
[0.295–0.722]
In-house ELISA/ 
Immundiagnostik 
ELISA
87% 0.697
[0.526–0.868]
Immundiagnostik 
ELISA / Theradiag 
ELISA
88% 0.726
[0.559–0.893]
(B) IFX
(>1 µg/ml)
 
In-house ELISA/ 
Theradiag ELISA
92% 0.840
[0.716–0.963]
In-house ELISA/ 
Immundiagnostik 
ELISA
96% 0.922
[0.836–1.000]
Immundiagnostik 
ELISA / Theradiag 
ELISA
92% 0.835
[0.709–0.960]
CI, confidence interval; ELISA, enzyme-linked immuno-
sorbent assay; IFX, infliximab.
Table 3. Agreement between different assays 
regarding levels of ADAs: (A) analytical approach and 
(B) clinical approach.
Agreement
 Accuracy KAPPA
[95% CI]
(A) ADAs
(>1.2 µg/ml for in-house and >0.01 µg/ml 
Theradiag; >10 AU for Immundiagnostik)
In-house/ Theradiag 85% 0.695
[0.539–0.851]
In-house/
Immundiagnostik
82% 0.643
[0.472–0.814]
Theradiag /
Immundiagnostik
82% 0.635
[0.463–0.807]
(B) ADAs
(>1.7 µg/ml for in-house and Theradiag; >10 AU/
ml for Immundiagnostik)
In-house/ Theradiag 81% 0.602
[0.435–0.769]
In-house/
Immundiagnostik
85% 0.692
[0.531–0.852]
Theradiag /
Immundiagnostik
83% 0.653
[0.492–0.814]
AU, arbitrary units; CI, confidence interval; ELISA, 
enzyme-linked immunosorbent assay; IFX, infliximab.
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However, the group of samples that had a double-
positive status for both IFX and ADAs were iden-
tified almost exclusively by the in-house and 
Immundiagnostik assays. Theradiag detected 
only three samples that were positive for ADAs in 
the presence of the drug. However, these three 
samples were considered IFX-negative by the 
other two assays.
Thereafter, we focused on the double status of 
IFX and ADAs. As the IFX/ADAs group defini-
tion depends directly on the cutoffs applied, the 
two different approaches (analytical and clinical) 
were taken into consideration. Tables 4 and 5 
show the agreement between assays for different 
combinations of IFX/ADA status from an analyti-
cal and clinical perspective, respectively.
IFX+/ADAs-. The analytical approach has shown 
that 50% of samples had an IFX+/ADAs-status 
(Table 4). Agreement between assays was consid-
ered good (85%).
The clinical perspective exhibited a strong agree-
ment ranging between 75.6 and 100% (Table 5). 
The poorest agreement between assays was 
observed when using Theradiag as the reference 
assay and Immundiagnostik as the confirmatory 
assay (75.6%).
IFX+/ADAs+. The double-positive samples 
obtained using the cutoffs given by the analytical 
perspective is shown in Table 4. The agreement 
was low (31.3–50%). The lowest agreement rate 
occurred for Theradiag and Immundiagnostik 
(considering Theradiag as the standard assay).
In contrast, for the double-positive status (IFX+/
ADAs+) defined using the clinical approach, 
there was a significant discrepancy between 
Theradiag and the in-house and Immundiagnostik 
assays. The in-house assay detected a total of 11 
double-positive sera and Immundiagnostik a total 
of 10 IFX+/ADAs+. Theradiag was able to 
detect three double-positive samples but neither 
were in agreement with the other assays. In fact, 
in those three samples, both the in-house and 
Immundiagnostik assay detected ADAs whereas 
IFX was considered undetectable.
IFX-/ADAs-. Using the analytical perspective 
(Table 4) only two or three double-negative sam-
ples were detected. Furthermore, Theradiag and 
the other two assays never agreed. The in-house 
and Immundiagnostik kit agreed in one out of 
three samples.
The detection of samples with double-negative 
status (IFX-/ADAs-) by clinical approach showed 
similar levels of agreement between pairs of assays 
(Table 5). When considering the in-house and 
Immundiagnostik assay there was 62.5% agree-
ment, but when considering Theradiag as the ref-
erence assay, there was a lower level of agreement 
between methodologies (50–55.6%).
IFX-/ADAs+. From an analytical perspective, 
Immundiagnostik and Theradiag had a good 
agreement (75–90%) concerning IFX-/ADAs+. 
A very good agreement was also obtained for this 
status between the in-house and Immundiagnos-
tik assays when considering in-house the stan-
dard test.
From the clinical point of view, IFX-/ADAs+ sta-
tus showed good agreement (more than 84%) 
between the in-house and Immundiagnostik assays. 
The in-house and Theradiag assays showed a lower 
level of agreement, although it was still considered 
good at 90.5% and 79.2%, respectively.
Exogenous IFX in ADA-positive samples
To evaluate the effect of IFX on in-house, 
Immundiagnostik and Theradiag assessment of 
ADAs in sera, an experiment was designed that 
involved spiking with exogenous IFX. The influ-
ence of exogenous IFX incubation time was 
assessed previously and no differences were found 
Figure 2. Levels of infliximab (IFX) and anti-infliximab 
antibodies (ADAs) determined by all methodologies. 
Dotted lines represent cutoffs for analytical approach 
(A, B, D, E and F) and clinical approach (C and D).
Cutoffs for IFX levels: (A) 0.1 µg/ml (in-house and 
Theradiag); (B) 0.5 µg/ml (Immundiagnostik); (C) 1 µg/ml (all 
assays).
Cutoffs for ADAs levels: (D) 1.7 µg/ml (in-house and 
Theradiag) and 10 AU/ml (Immundiagnostik); (E) 1.2 µg/ml 
(in-house); (F) 0.01 µg/ml (Theradiag).
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(data not shown). An incubation time of 30 min 
was selected for further experiments.
Evaluation of ADA levels with exogenous IFX spik-
ing in four groups of sera samples. To evaluate 
whether different intrinsic concentrations of 
ADAs are important when assessing the influence 
of exogenous IFX, we used stratified concentra-
tions of ADA levels in sera (four different groups 
as evaluated previously: 1.7–3, 3–10, 10–25 and 
>25 µg/ml) and spiked them with exogenous 
IFX. The evaluation was performed using the in-
house assay only. The results are presented in Fig-
ure 3. In-house assay lost the capability to detect 
levels of antibodies in sera samples with ADA lev-
els between 1.7 and 3 µg/ml at concentrations of 
IFX over 5 µg/ml. The influence of exogenous 
IFX was also evident in the 3–10 µg/ml group, but 
loss of antibody detection capacity was only 
observed beyond 100 µg/ml IFX, which generally 
exceeds the therapeutic concentrations of inflix-
imab in vivo even during induction phase [Ade-
dokun et  al. 2014]. A decreased ADA detection 
capacity was observed in the two upper groups 
(10–25 and >25 µg/ml) in a concentration-
dependent manner, but in both groups the in-
house assay was able to detect antibodies even 
with 300 µg/ml of exogenous IFX. Nevertheless, a 
significant reduction of detection capacity of 75% 
and 61% was observed in the 10–25 µg/ml and 
>25 µg/ml groups, respectively.
Evaluation of ADA levels with exogenous IFX spiking 
in two groups: high and intermediate levels of 
ADAs. Taking into account the above-mentioned 
results, we decided to explore the performance of 
Table 4. Agreement between the three assays for all combinations of IFX/ADAs status (analytical approach).
Agreement
 Accuracy KAPPA
[95% CI]
In-house assay versus Theradiag assay(a) Theradiag assay versus In-house 
assay(b)
 
IFX + ADA–
85% (n = 40)
IFX + ADA +
38.1% (n = 21)
IFX + ADA –
85% (n = 40)
IFX + ANTI +
50% (n = 16)
68% 0.502
[0.355–0.649]
IFX - ADA –
0% (n = 2)
IFX – ADA +
75.0% (n = 16)
IFX - ADA –
0% (n = 2)
IFX – ADA+
57.1% (n = 21)
 
In-house assay versus Immundiagnostik(c) Immundiagnostik assay versus In-
house assay(d)
 
IFX + ADA –
85.0% (n = 40)
IFX + ADA +
35.0% (n = 20)
IFX + ADA –
85.0% (n = 40)
IFX + ADA +
58.3% (n = 12)
72% 0.566
[0.425–0.707]
IFX - ADA –
33.3% (n = 3)
IFX – ADA +
93.8% (n = 16)
IFX - ADA –
33.3% (n = 3)
IFX – ADA +
62.5% (n = 24)
 
Immundiagnostik assay versus Theradiag 
assay(e)
Theradiag assay versus 
Immundiagnostik(f)
 
IFX + ADA –
84.6% (n = 39)
IFX + ADA +
41.7% (n = 12)
IFX + ADA –
82.5% (n = 40)
IFX + ADA +
31.3% (n = 16)
77% 0.562
[0.415–0.707]
IFX - ADA –
0.0% (n = 2)
IFX – ADA +
75.0% (n = 24)
IFX - ADA –
0.0% (n = 1)
IFX – ADA +
90.0% (n = 20)
 
(a)In-house assay was considered the reference assay and it was evaluated whether Theradiag confirmed the double status result.
(b)Theradiag assay was considered the reference assay and it was evaluated whether in-house confirmed the double status result.
(c)In-house assay was considered the reference assay and it was evaluated whether Immundiagnostik confirmed the double status result.
(d)Immundiagnostik assay was considered the reference assay and it was evaluated whether in-house confirmed the double status result.
(e)Immundiagnostik assay was considered the reference assay and it was evaluated whether Theradiag confirmed the double status result.
(f)Theradiag assay was considered the reference assay and it was evaluated whether Immundiagnostik confirmed the double status result.
CI, confidence interval.
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the three assays under the interference of exoge-
nous IFX. The two most representative groups 
were used: samples with ADAs within 3–10 µg/ml 
(intermediate) and those with >25 µg/ml (high 
level). Figures 4 and 5 present the results of the 
groups spiked with exogenous IFX at different con-
centrations (0, 5, 10, 15, 30, 100 and 300 µg/ml). 
Table 6 shows the half maximal inhibitory con-
centrations (IC50).
Figure 4 (high levels of ADAs) illustrates that 
exogenous IFX only interfered with ADA detec-
tion at concentrations higher than 100 µg/ml. 
Spiking 100 µg/ml of exogenous IFX in sera sam-
ples with high levels of ADA resulted in a decline 
in ADA detection of 87%, 46% and 16% in the 
Theradiag, in-house and Immundiagnostik assays, 
respectively. Nevertheless, in-house showed a 
higher IC50 than Theradiag, at 143.6 µg/ml versus 
74.9 µg/ml, respectively, indicating that it was less 
affected than Theradiag by the presence of IFX. 
In the Immundiagnostik assay the influence of 
exogenous IFX showed a lower decline in ADA 
detection. In fact, 300 µg/ml decreased ADA 
detection by 17% (the IC50 was therefore impos-
sible to determine), while in in-house and 
Theradiag assays, ADA detection decreased by 
75% and 93%, respectively. However, all method-
ologies were able to detect ADAs, in sera origi-
nally positive for high levels of ADAs, even with 
300 µg/ml of exogenous IFX.
Figure 5 shows exogenous IFX interference in 
sera samples with intermediate levels of ADAs. 
The presence of exogenous IFX decreased ADA 
detection in Theradiag and in-house with the 
Table 5. Agreement between the three assays for all combinations of IFX/ADAs status (clinical approach). 
Agreement 
 Accuracy KAPPA
[95% CI]
In-house assay versus Theradiag 
assay(a)
Theradiag assay versus In-house assay(b)  
IFX + ADA–
100% (n = 35)
IFX + ADA +
0% (n = 11)
IFX + ADA –
77.8% (n = 45)
IFX + ANTI +
0% (n = 3)
76% 0.620
[0.489–0.751]
IFX - ADA –
62.5% (n = 8)
IFX – ADA +
79.2% (n = 24)
IFX - ADA –
55.6% (n = 9)
IFX – ADA+
90.5% (n = 21)
 
In-house assay versus 
Immundiagnostik(c)
Immundiagnostik assay versus In-house 
assay(d)
 
IFX + ADA –
83.8% (n = 37)
IFX + ADA +
54.5% (n = 11)
IFX + ADA –
88.6% (n = 35)
IFX + ADA +
60% (n = 10)
81% 0.716
[0.591–0.841]
IFX - ADA –
62.5% (n = 8)
IFX – ADA +
95.7% (n = 23)
IFX - ADA –
62.5% (n = 8)
IFX – ADA +
84.6% (n = 26)
 
Immundiagnostik assay versus 
Theradiag assay(e)
Theradiag assay versus 
Immundiagnostik(f)
 
IFX + ADA –
100% (n = 34)
IFX + ADA +
0% (n = 10)
IFX + ADA –
75.6% (n = 45)
IFX + ADA +
0% (n = 3)
76% 0.625
[0.491–0.758]
IFX - ADA –
66.7% (n = 6)
IFX – ADA +
76.9% (n = 26)
IFX - ADA –
50% (n = 8)
IFX – ADA +
100% (n = 20)
 
(a) In-house assay was considered the reference assay and it was evaluated whether Theradiag confirmed the double status result.
(b) Theradiag assay was considered the reference assay and it was evaluated whether in-house confirmed the double status result.
(c) In-house assay was considered the reference assay and it was evaluated whether Immundiagnostik confirmed the double status result.
(d) Immundiagnostik assay was considered the reference assay and it was evaluated whether in-house confirmed the double status result.
(e) Immundiagnostik assay was considered the reference assay and it was evaluated whether Theradiag confirmed the double status result.
(f) Theradiag assay was considered the reference assay and it was evaluated whether Immundiagnostik confirmed the double status result.
CI, confidence interval.
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lower concentration (5 µg/ml) of exogenous IFX. 
For Theradiag this decrease led to the inability to 
detect ADAs and consequently it was impossi-
ble to determine the IC50. In-house showed an 
IC50 of 0.88 µg/ml while Immundiagnostik 
showed a higher value of 140.1 µg/ml. At 300 
µg/ml the interference was stronger in Theradiag 
(97%) while in in-house detection decreased by 
74%. In-house failed to detect ADAs at IFX 
concentrations of 300 µg/ml, which are above 
the therapeutic levels achieved in vivo. Above 
30 µg/ml IFX the Immundiagnostik assay was 
influenced by an additive concentration effect 
but was able to detect ADAs even at the higher 
concentration (300 µg/ml) of exogenous IFX 
(total decrease of 60%).
Figure 3. Stratified anti-infliximab antibodies (ADA) 
levels in the presence of exogenous infliximab 
(IFX), evaluated by in-house assay. Therapeutic IFX 
concentrations range was considered between 0 and 
100 µg/ml [Adedokun et al. 2014].
Figure 4. High anti-infliximab antibodies (ADAs) levels in the presence of exogenous infliximab (IFX) evaluated 
by in-house, Immundiagnostik and Theradiag assay. Therapeutic IFX concentrations range was considered 
between 0 and 100 µg/ml [Adedokun et al. 2014].
Figure 5. Intermediate anti-infliximab antibodies (ADAs) levels in the presence of exogenous infliximab (IFX) 
evaluated by in-house, Immundiagnostik and Theradiag assay. Therapeutic IFX concentrations range was 
considered between 0 and 100 µg/ml [Adedokun et al. 2014].
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IgG4 ADAs
In order to evaluate the influence of IgG4 ADAs, 
samples positive for ADAs were tested for the 
presence of IgG4. IgG4 ADAs were found in 
54.8% of the ADA-positive samples. Figure 6 
shows the levels of IFX and IgG4 in samples that 
were ADA-negative with Theradiag but ADA-
positive for both the in-house and Immundiagnostik 
assays. Of the eight samples negative for antibod-
ies with Theradiag, five presented positive levels 
of IFX and three presented IgG4 ADAs.
Discussion
Several methodologies are available for use in drug 
monitoring. However, different methodologies 
return different results. There is still little informa-
tion comparing different assays, in particular for 
ADA detection, which is susceptible to interfer-
ence in the presence of detectable levels of IFX.
The aim of this study was to evaluate and com-
pare three different assays for detecting IFX and 
ADAs and to clarify the importance of the pres-
ence of detectable levels of IFX on the accuracy 
of the ADA assays.
Cutoffs for a qualitative evaluation of the assays 
are difficult to establish, particularly for ADAs 
assays. In fact, ADAs results are expressed in dif-
ferent units by the different assays. In addition, 
Immundiagnostik defines a cutoff for positivity 
that is different from the limit of detection and not 
suggested by all commercial assays. The manufac-
turers’ instruction for Theradiag do not contain 
any suggestion for a cutoff for ADAs positivity 
besides the limit of detection of 0.01 µg/ml. Van 
Schouwenburg and colleagues have shown that BE 
assays (Theradiag methodology) performance is 
depend not only of the amount of antibody in the 
serum but also of the affinity of ADAs to the assay 
[Van Schouwenburg et al. 2016]. This indicates a 
possible source of intervariability of the assay, 
namely for values near the limit of detection. In 
fact, our results show that with Theradiag 70% of 
the values considered to be positive, with analytical 
approach, are between 0.01 and 0.04 µg/ml. This 
might be a reflection of the intervariability of the 
assay, rather than a faithful quantification of the 
presence of antibodies. Taking this into considera-
tion, we have decided to perform two different 
approaches in the qualitative analyses of the results: 
an analytical one, in which cutoffs were defined by 
the manufacturers’ instructions; and a clinical one, 
in which the cutoffs were defined according to the 
literature.
From an analytical perspective, IFX assays 
showed a substantial agreement and a good 
accuracy, although the in-house and Theradiag 
methods had only a moderate agreement. On the 
other hand, upon applying a cutoff of 1 µg/ml, 
the behavior of the three assays is very similar. 
Table 6. Infliximab (IFX) inhibition effect on ADAs at intermediate and high levels in different assays.
IC50 (µg/ml)
 Intermediate levels
3 µg/ml > ADA <10 µg/ml
High levels
ADA >25 µg/ml
In-house (AHLC) 0.88 143.60
Immundiagnostik (SPFE) 140.10 NA
Theradiag (BE) NA 74.89
IC50, half maximal inhibitory concentration; NA, IC50 value not determined because either 50% inhibition fell outside the 
highest concentration or because inhibition was 100% above the lowest concentration of IFX; ADA, anti-infliximab anti-
bodies; AHLC, anti-human lambda chain; SPFE, semi-fluid phase enzyme; BE, bridging enzyme-linked immunosorbent 
assay.
Figure 6. Levels of IFX and IgG4 in samples that were 
ADA-negative in Theradiag and ADA-positive in both 
the in-house and Immundiagnostik assays.
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This suggests that using the limit of detection as 
a cutoff may decrease the quality agreement 
between assays.
The behavior of the three assays in terms of IFX 
determination was very similar. In fact, an accu-
racy of over 92% for IFX was observed when ana-
lyzing the agreement between the three assays. An 
agreement of 100% (data not shown) was 
observed between the in-house and 
Immundiagnostik assays for IFX-negative sam-
ples, while the Theradiag assay identified four 
IFX-positive samples that the other two assays 
returned as negative. Casteele and colleagues also 
evaluated three IFX assays based on the sandwich 
ELISA principle and found good correlation 
between them [Casteele et al. 2012]. The authors 
used the same commercial kit as used here 
(Theradiag). In fact, Theradiag returned 11 posi-
tive samples that were negative according to the 
other two assays, showing that this assay can 
detect nonspecific binding. Overall, high titers in 
one assay were also high in the other two assays. 
Nevertheless, the Immundiagnostik and in-house 
assays were able to detect higher levels of IFX in 
sera samples, which may indicate the use of a 
more specific anti-human IgG antibody in the 
detection step in these assays than in Theradiag. 
The agreement between the three assays seemed 
to be more qualitative than quantitative. The 
three methodologies use the same ELISA sand-
wich principle, but there are some idiosyncratic 
differences that can explain the small discrepan-
cies in quantitative evaluation: different detection 
limits and test sensitivity; reagent stability; differ-
ent calibration standards and curve adjustment; 
and different sample dilution, manipulation and 
processing (e.g. different incubation times). 
Nevertheless, from a clinical point of view, the 
information given by the three assays (presence of 
positive/negative levels; low/therapeutic/high lev-
els of the drug) showed acceptable interassay 
agreement. However, clinicians should be aware 
that changing drug level assays during patient fol-
low up could induce errors in the interpretation of 
results and subsequent therapeutic strategies.
ADAs were evaluated using three methodologies: 
in-house AHLC, Immundiagnostik SFPE and 
Theradiag BE. These three assays have different 
methodological principles. The in-house AHLC 
is a sandwich ELISA that uses anti-human 
lambda chain conjugate antibody in the detection 
step, benefitting from IFX kappa chain exclusive 
composition [Kopylov et al. 2012]. The Theradiag 
BE uses a double-antigen bridge: ADAs create a 
bridge between IFX immobilized on the plate 
and IFX enzyme-linked conjugate. The 
Immundiagnostik SFPE uses an initial acid buffer 
treatment to dissociate the IFX–ADA immune 
complexes and two IFX conjugates with different 
types of conjugates. Acidified samples are incu-
bated with an IFX–biotin conjugate, which 
immobilizes ADAs to the plate, whilst an IFX–
peroxidase conjugate is used for detection.
A total of 79 samples of sera were compared using 
the three assays. The analytical approach showed 
the same moderate agreement for the three assays 
than the clinical approach. However, and from 
the analytical perspective, Theradiag was able to 
detect 37 positive ADAs, whereas from a clinical 
perspective only 24 patients were considered to 
be positive for ADAs. Conversely, the in-house 
assay detected almost the same number of ADA-
positive patients with the two approaches (34 for 
analytical versus 37 for clinical). The results 
obtained using a clinical perspective with the 
Theradiag kit suggest a high rate of false-negative 
outcomes. This high prevalence of false-negative 
outcomes with Theradiag was reported previ-
ously by other authors [Imaeda et  al. 2012; 
Steenholdt et al. 2013]. Kopylov and colleagues 
reported that BE was unable to detect ADAs in 
the presence of IFX [Kopylov et al. 2012]. Our 
results showed that 22 out of 24 ADA-positive 
samples were IFX-negative. Only three patients 
showed a double-positive status with Theradiag, 
however neither was confirmed as IFX-positive in 
the in-house or Immundiagnostik assay. These 
samples were probably false positive for IFX. In 
fact, the disagreement of the in-house and 
Immundiagnostik assay with Theradiag for dou-
ble-positive status (IFX+/ADAs+) was 100%. 
Since Theradiag uses labeled IFX as the detec-
tion antibody, the presence of IFX may compete 
with the detection of the ADAs. On the other 
hand, the BE is unable to detect monovalent 
IgG4 ADAs, contributing to the false-negative 
results. Our results were consistent with these two 
statements and showed that samples positive for 
ADAs with the in-house and Immundiagnostik 
assays, but negative with Theradiag, one of two 
situations occurred: (i) sera samples were IFX-
positive; or (ii) ADAs were IgG4 antibodies. The 
inability to detect antibodies in the presence of 
the drug is important as two recent studies have 
shown that patients with IFX levels >3 µg/ml but 
with positive ADA have significantly higher levels 
of C-reactive protein (CRP) and less mucosal 
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healing [Casteele et al. 2015; Yanai et al. 2015], 
indicating a reduced control of inflammation 
mediated by these antibodies even when drug lev-
els are adequate.
In order to understand the influence of drug pres-
ence on ADA detection, we designed an experi-
ment using IFX-negative sera that were incubated 
with different concentrations of exogenous IFX. 
The in-house assay was slightly affected by 5 µg/ml 
exogenous infliximab but was able to detect anti-
bodies up to 100 µg/ml of IFX. Kopylov and col-
leagues described the same drug concentration 
dependency for the AHLC assay [Kopylov et  al. 
2012]. However, our results permit us to define 
which concentration of IFX decrease the assay 
capacity to determine ADAs. The Immundiagnostik 
assay showed the best behavior in the presence of 
exogenous IFX. Interference was observed above 
100 µg/ml of exogenous IFX but the assay was able 
to detect ADAs even at the higher concentration of 
300 µg/ml of IFX. However, the results obtained in 
sera with high levels of ADAs were surprising and 
to the best of the authors’ knowledge have not 
been reported previously. Even the Theradiag BE, 
which is widely described as being unable to detect 
antibodies in the presence of the drug, was able to 
identify ADA-positive samples in the presence of 
high levels of exogenous IFX. The results indi-
cated that assays are not only limited by the levels 
of drug in the sera but also by the concentration of 
ADAs. These phenomena could be explained as 
follows: (i) in Theradiag, ADAs bind to all free 
drug in serum but there is still enough ADAs to 
bind to the plated IFX and bridge it to the conju-
gated one; (ii) in Immundiagnostik high levels of 
ADAs are most likely to diminish free IFX 
interference.
In summary, for IFX drug level determination, 
the three methodologies are equivalent, however 
the agreement between them seems to be more 
qualitative than quantitative. Regarding ADAs, 
despite being equally effective, the three assays 
show significant differences. Disagreement 
increased when samples had a double-positive or 
double-negative status, probably related to the 
specific limitations of each assay. The choice of 
cutoff to discriminate positive versus negative also 
enhances disagreement. This led us to define two 
different approaches with different cutoffs and 
present both evaluations. Clinical approach seems 
to highlight inabilities of the assays. In fact, 
Theradiag showed inability to detect positive 
ADA levels in samples with IFX (<5 µg/ml) or a 
high percentage of IgG4 ADAs. IgG4 ADAs are 
monovalent and unable to create a bridge with the 
labeled IFX used in detection step. In contrast, 
both the in-house assay and the Immundiagnostik 
assay are able to detect ADAs in the presence of 
IFX up to levels of >100 µg/ml which conform 
with the therapeutic concentrations observed in 
patients receiving IFX. Unexpectedly, in samples 
with high levels of ADAs (>25 µg/ml), the pres-
ence of IFX was not as important and even 
Theradiag was able to detect antibodies. 
Nevertheless, Immundiagnostik was least affected 
by IFX, followed by the in-house assay. In conclu-
sion, our results indicated that assays are not only 
limited by the levels of drug in the sera but also by 
the concentration of ADAs.
Clinicians must be aware when optimizing treat-
ment that binary (IFX/ADAs) stratification of 
results as positive and negative can differ accord-
ing to the assay used. There is a strong agreement 
between assays for IFX+/ADAs- and IFX-/
ADAs+ status. The choice of assay will probably 
have little influence on therapeutic decisions to 
change the class of drug (IFX+/ADA-) or change 
anti-TNFα antibody (IFX-/ADAs+). However, 
erroneous therapeutic decisions may occur when 
patients show double-negative or double-positive 
status, since agreement between assays is signifi-
cantly lower in these circumstances. Treatment 
intensification (IFX-/ADAs-) and change of drug 
class or concomitant use of immunomodulators 
(IFX+/ADAs+) should take into account the fact 
that the results are assay dependent.
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